Daily Mail: New drug for aggressive lung cancer will extend patients’ lives
Scientists have found the best cure for an aggressive type of lung cancer. It has been proven that it helps to live without progression of the disease for an average of five years, reported Daily Mail edition.
Experts have already named the new drug Lorlatinib the best cure for aggressive ALK-positive lung cancer. Scientists expect that the medicine will extend the life of patients by at least several years. The drug binds to the ALK protein on the surface of cancer cells and stops their growth
The effectiveness of the drug was proven during trials involving 296 people with ALK-positive non-small cell lung cancer. The mutation found in them in the ALK gene increases the risk of metastases in the brain. Moreover, 25 percent of the participants in the scientific study already had metastases.
During the experiment, it was found that six out of ten patients who took Lorlatinib daily lived for five years without disease progression. In half of the patients taking other medications, disease progression was recorded in less than a year.
At the same time, the study authors admitted that it is impossible to say how much the medicine can prolong life, since many study participants continue to live without negative changes in their health.
The drug has been prescribed to patients with lung cancer since 2020, but only to those who have not responded to other therapies. However, the new research could lead to wider use of the drug.
Related materials:
Earlier, oncologist Khamis Magomedova warned that chronic lack of sleep can trigger the development of cancer. According to her, the habit of sleeping little and going to bed after 23:00 causes circadian stress.
#Scientists #cure #aggressive #type #cancer
